[BIC-announce] FW: Killam Lecture - Tuesday, Dec. 12th @ 4:00 pm - Speaker: Peter Forsyth

[Jennifer Chew, Ms.]

 PLEASE DISCARD IF THIS IS A DUPLICATE.  THANK YOU.  JENNIFER   
________________________________

From: MNISTAFF - Montreal Neurological Institute Staff
[mailto:MNISTAFF at LISTS.MCGILL.CA] On Behalf Of Felicia Callocchia, Ms.
Sent: Monday, December 11, 2006 4:20 PM
To: MNISTAFF at LISTS.MCGILL.CA
Subject: Killam Lecture - Tuesday, Dec. 12th @ 4:00 pm - Speaker: Peter
Forsyth
Importance: High


KILLAM LECTURE
 
 
Speaker:   Peter Forsyth, MD
                Department of Oncology and Clinical Neurosciences
                The University of Calgary 
 
Title:         Oncolytic Viruses and Invasion in Gliomas 
 
Place:        de Grandpre Communication Centre
 
Date:        Tuesday, December 12, 2006
 
Time:        4:00 pm 
  
________________________________


Malignant glioma is a highly aggressive form of human brain tumor with a
dismal prognosis. The Forsyth laboratory is investigating the molecular
mechanisms that regulate glioma invasion. In addition, they are
exploring the application of oncolytic viruses as potential therapeutics
for brain tumors. In this capacity, they are interested in the
possibility that certain common viruses exhibit a capacity to
selectively attack cancer cells. Peter is an engaging speaker and his
lecture will address issues related to brain tumor biology, cell
motility, and viral oncology.    
 
Selected Recent Publications  
Lun X, Senger DL, Alain T, Oprea A, Parato K, Stojdl D, Lichty B, Power
A, Johnston RN, Hamilton M, Parney I, Bell JC, Forsyth PA.
<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&do
pt=AbstractPlus&list_uids=17077357&query_hl=17&itool=pubmed_docsum>
Effects of intravenously administered recombinant vesicular stomatitis
virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer
Inst. 2006 Nov 1;98(21):1546-57. 
Parato KA, Senger D, Forsyth PA, Bell JC.
<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&do
pt=AbstractPlus&list_uids=16294217&query_hl=17&itool=pubmed_docsum>
Recent progress in the battle between oncolytic viruses and tumours. Nat
Rev Cancer. 2005 Dec;5(12):965-76.  
Lun X, Yang W, Alain T, Shi ZQ, Muzik H, Barrett JW, McFadden G, Bell J,
Hamilton MG, Senger DL, Forsyth PA.
<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&do
pt=AbstractPlus&list_uids=16267023&query_hl=17&itool=pubmed_docsum>
Myxoma virus is a novel oncolytic virus with significant antitumor
activity against experimental human gliomas. Cancer Res. 2005 Nov
1;65(21):9982-90.  
Yang WQ, Senger DL, Lun XQ, Muzik H, Shi ZQ, Dyck RH, Norman K, Brasher
PM, Rewcastle NB, George D, Stewart D, Lee PW, Forsyth PA.
<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&do
pt=AbstractPlus&list_uids=15372068&query_hl=17&itool=pubmed_docsum>
Reovirus as an experimental therapeutic for brain and leptomeningeal
metastases from breast cancer. Gene Ther. 2004 Nov;11(21):1579-89.

 

-------------- next part --------------
An HTML attachment was scrubbed...
URL: http://www.bic.mni.mcgill.ca/pipermail/bic-announce/attachments/20061212/773fed39/attachment.html